Patent thicket strategy with terminal disclaimers helps block biologic competition, JAMA letter shows
Biologics developers are protecting their most lucrative assets with a particular type of patent that they can quickly pile up and drive costly litigation around …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.